The main activities of PharmaDiall is the search, development, chemical synthesis, in vitro testing, animal testing (prior to clinical trials), organization of clinical trials (1st and 2nd phases) and patenting of new biologically active chemicals capable of turning into medicines in the future.
We have obtained results for the 3rd group of volunteers in the 1st phase of clinical trials of the Amidine hydrochloride dosage form (DD217). Number of volunteers - 6 people. Administration - 60 mg once, orally. Preliminary results - serious adverse events haven’t been observed.
We have obtained results for the 2nd group of volunteers in the 1st phase of clinical trials of the Amidine hydrochloride dosage form (DD217). Number of volunteers - 6 people. Administration - 40 mg once, orally. This is the 2nd group of volunteers in the 1st phase of clinical trials. Preliminary results - serious adverse events haven’t been observed.
In the USA, a decision to issue a patent on application No. 13/599.038 was taken. This is a patent for substance DD217 and related compounds - “Urethanes, ureas, amides and related scale preventers of Xa factor".
